Background: The global obesity epidemic has implications for kidney transplantation. There are conflicting reports regarding the impact of obesity on long-term post-transplant outcomes. Aim: To explore the impact of body mass index (BMI) on long-term outcomes after kidney transplantation. Design: The association between BMI and cardiovascular disease, cancer, post-transplant diabetes mellitus, graft and recipient survival was investigated in recipients who had been transplanted at least ten years previously. Methods: All consecutive adult renal transplant recipients who received first, deceased donor, transplants between 1986 and 2005 in Northern Ireland were followed-up until 2016. Results: A total of 328 patients were eligible. Of them, 96 were overweight with a BMI 25.0-29.9 kg/m 2 , and 56 were obese
Introduction
It is estimated that more than 600 million people worldwide currently have a body mass index (BMI) exceeding 30 kg/m 2 , 1 and this prevalence continues to rise.
1
The global obesity epidemic has implications for kidney transplantation. The proportion of kidney transplant recipients with a BMI 30 kg/m 2 is doubling every 15 years 2 and in 2011
35% of United States kidney transplant recipients were classified as obese. 2 End stage renal disease (ESRD) is also becoming more common. 3 The epidemic of obesity contributes to this because of the association between obesity, type 2 diabetes mellitus and hypertension. Diabetic nephropathy is the most common cause of ESRD in the UK population, accounting for 27% of incident patients on renal replacement therapy (RRT). 3 It is well established that kidney transplantation offers a survival advantage compared to dialysis for patients with ESRD. 4 Whether obese patients are 'suitable' for transplantation remains a matter for debate. There are conflicting reports regarding the impact of obesity on post-transplant complications, graft survival and recipient survival. [5] [6] [7] [8] [9] [10] In the general population undergoing abdominal surgery, obesity is associated with more frequent anaesthetic complications, increased incidence of wound infection and prolonged hospital stay. 11 In renal transplantation, some studies have reported that recipient obesity is associated with a higher incidence of delayed graft function 6, 11 and potentially premature graft loss. 12 There is some evidence that kidney transplantation confers a similar survival benefit in obese and non-obese recipients when compared to maintenance dialysis in the first year post-transplant 12 but there is a paucity of evidence regarding the impact of obesity on long-term outcomes.
Theoretically obesity could influence long-term graft survival by a number of mechanisms. In the general population, obesity is associated with a reduced glomerular filtration rate and the development of proteinuria by a number of mechanisms. [13] [14] [15] [16] Graft damage by comparable mechanisms after transplantation could be anticipated. Obesity may also alter the metabolism and bioavailability of immunosuppressive medication, potentially increasing the risk of chronic immunological injury. 7 The most common causes of long-term morbidity and mortality in transplant recipients are cardiovascular disease 17 and cancer. 18 In the non-transplant population, obesity is a cardiovascular risk factor both independently and via its association with hypertension, hyperlipidaemia and type 2 diabetes mellitus. 19 Several studies have demonstrated that obese kidney transplant recipients have an increased incidence of posttransplant diabetes mellitus 20 but whether this translates into an increased risk of cardiovascular disease or affects overall patient survival remains undetermined. In a single centre study of 1800 kidney transplant recipients followed-up for 8 years, post-transplant diabetes mellitus was associated with reduced patient survival (hazard ratio (HR) 1.8). This relationship was independent of recipient age, transplant year and gender. 21 However, this study did not examine whether the reduced survival associated with post-transplant diabetes mellitus was independent of allograft survival. In the literature, there are no suitably powered studies with adequate follow-up to ascertain whether post-transplant diabetes mellitus leads to increased recipient mortality independently of allograft survival.
In the general population, both obesity and type 2 diabetes are associated with increased incidence of, and mortality from, cancer. 22 There is limited published data that explores the association between obesity and risk of malignancy in the kidney transplant population, but there is evidence in liver transplant recipients that obesity is an independent risk factor for non-skin solid tumours. 23 This study aims to assess the impact of BMI at the time of transplantation on the incidence of post-transplant diabetes mellitus, cardiovascular disease, malignancy, graft and recipient survival at a minimum of 10 years post renal transplantation. 
Patients and methods

Patients
Body mass index
The recipient's weight at the first outpatient review following transplantation (to minimize the effect of variation in fluid status in the perioperative period) was used in conjunction with height recorded at first renal assessment to calculate BMI.
Immunosuppression
Prednisolone and azathioprine was the dual immunosuppressive therapy used for all new renal transplant recipients until 1989. Subsequently calcineurin inhibitor-based maintenance therapy (with ciclosporin and later tacrolimus) was introduced. After mycophenolate mofetil became available in 1998, approximately one quarter of patients had calcineurin inhibitor free maintenance regimens. Induction therapy was not used at this transplant centre during the study period.
Outcome measures
Post-transplant diabetes mellitus Post-transplant diabetes mellitus was defined as the commencement of an oral hypoglycaemic agent or insulin post-transplant.
Cardiovascular complications
The diagnosis of a cardiovascular complication necessitated physician documentation and objective evidence of the complication. For example, a diagnosis of 'myocardial infarction' would require clinical documentation with a corresponding electrocardiogram, elevation in cardiac enzymes or record of subsequent confirmatory angiography. Included was coronary artery disease (myocardial infarction, symptoms requiring percutaneous intervention or bypass surgery), new arrhythmia, symptomatic valvular disease, ischaemic stroke or peripheral vascular disease with intervention.
Cancer
The diagnosis of malignancy required physician documentation and objective evidence. For example, 'skin cancer', would require histological confirmation of an abnormal lesion.
Graft survival
This was defined as the time from transplantation to commencement of dialysis, a pre-emptive further transplant, death or 1st December 2016. Death-censored graft survival excluded death as a cause of transplant loss.
Recipient survival
This was defined as the time from transplantation until death or 1st December 2016. Factors associated with the development of post-transplant complications were investigated using the Chi-squared test, independent t-test and logistic regression analysis. Graft and recipient survival were analysed using KaplanMeier survival plots. The characteristics of grafts that were associated with survival were investigated by means of the logrank test. Factors included in the analysis included recipient age and gender, recipient BMI, pre-transplant smoking status, pre-transplant RRT duration, donor age and gender, HLA mismatch and cold ischaemic time. In the same manner, the variables associated with recipient survival were determined. The significant factors were then incorporated into a Cox proportional hazards model with stepwise backward elimination.
Statistical analysis
Values of P < 0.05 were considered statistically significant. SPSS for Windows V R (SPSS V R Inc., Chicago, IL, USA) version 22.0 was employed for all analyses.
Results
Demographics
There were 529 adult patients who received their first deceased donor renal transplant in Belfast between 1986 and 2005. The median follow-up time was 16.7 years.
Two patients transferred care to another centre and longterm follow-up data is unavailable. Of the remaining 527 patients' BMI was available for 328 (62%) of patients. About 66% of recipients were male (Table 1) . Median age of transplantation was 41 years (range 18-73 years) with a median RRT duration prior to transplantation of 16 months (range 0-117 months). At the time of transplantation 55% of patients had never smoked, 20% were current smokers, 20% were ex-smokers and in 5% of cases the smoking status was unknown.
In regard to the donors, 57% were male and the median age was 39 years (range 18-75 years). The median cold ischaemic time was 1300 min (range 658-2802 min) and almost all were well-matched (93% of transplants had three or fewer HLA mismatch antigens at the A, B and DR loci). (Table 1) .
Body mass index
Graft survival
There were 183 cases of graft loss during the follow-up period. The median graft survival was 164 months (range 0-347 months). In univariate analysis recipient age, smoking status and donor age were associated with graft loss. In multivariate analysis, donor age and recipient smoking status remained significant factors affecting graft loss. Graft survival was not associated with recipient BMI (Figure 2 , Table 2 ).
Death-censored graft survival
There were 41 cases of death-censored graft loss in the followup period. The median death-censored graft survival was 111 months (range 24-239 months). In both univariate and multivariate analysis donor age and recipient smoking status were associated with death-censored graft loss. Duration of RRT time prior to transplantation (P ¼ 0.02) was a significant factor in univariate analysis only. Recipient BMI was not associated with death-censored graft survival (Table 2) .
Recipient survival
There were 115 deaths in the follow-up period. The median recipient survival was 200 months (range 24-364 months). In univariate analysis, recipient age, BMI, smoking status, donor age, HLA mismatch and cold ischaemic time were associated with recipient survival; however, in multivariate analysis, recipient age and donor age were the only factors that remained associated with recipient survival. BMI was not associated with recipient survival (Table 2) .
Post-transplant complications
There were 28 patients with diabetes mellitus prior to transplantation. Of the remaining 300 recipients, 49 (16.3%) developed post-transplant diabetes mellitus. Cancer was diagnosed in 154 (47.0%) of recipients post-transplant of whom 79 (51.3%) had non-skin cancer malignancies, 51 (33.1%) had skin cancer alone and 24 (15.6%) had a combination of both. New onset cardiovascular disease was identified in 132 (40.2%) of the cohort.
Post-transplant diabetes mellitus
In both univariate and multivariate analysis, recipient BMI was the only variable associated with the development of posttransplant diabetes mellitus (Table 3) .
Cardiovascular disease
In univariate analysis, recipient age (P < 0.01) and smoking status (P ¼ 0.002) were associated with cardiovascular disease post-transplant, however, in multivariate analysis, recipient age was the only factor associated with the development of cardiovascular disease (Table 3) . Recipient BMI was not a statistically significant factor influencing the development of cardiovascular disease post-transplant (Table 3) .
Cancer
In both univariate and multivariate analysis recipient age and BMI are statistically significant factors which influence developing malignancy post-transplant (Table 3 ). Notably cancer was less common in recipients with a higher BMI (adjusted OR 0.58).
Discussion
Kidney transplantation is the optimal treatment for the expanding ESRD population, but the demand for donor kidneys outstrips supply. The identification of modifiable factors which limit the longevity of graft and recipient survival is important to ensure the optimal use of this scarce resource. Some transplant centres have reservations about routinely offering kidney transplantation to obese recipients because of the concern regarding adverse short and long-term graft and recipient outcomes in this group. [5] [6] [7] [8] [9] As the worldwide prevalence of obesity continues to increase it is essential that the impact of recipient obesity on long-term graft and recipient outcomes is established. This study found that recipient BMI at the time of transplantation was associated with an increased incidence of post-transplant diabetes mellitus but not with cardiovascular disease or cancer. Graft and recipient survival were not significantly different between obese and non-obese recipients at a median follow-up of 16 years. Cardiovascular disease and cancer remain the most common causes of death in renal transplant recipients. 17, 18 As both obesity and diabetes mellitus are independent risk factors for cardiovascular disease in the general population it would be anticipated that obese transplant recipients have an increased incidence of cardiovascular disease. However, this was not found in this study of over 300 patients with long-term follow up. There may be a number of reasons for this. First, this absence of association may relate to inherent selection bias. Transplant recipients undergo rigorous assessment prior to activation on the transplant waiting list and those with significant cardiovascular disease may not be listed. It is possible that there were other obese individuals who were assessed for transplantation but declined as a consequence of the cardiovascular morbidity. However, the same assessment and acceptance criteria occurred for non-obese persons, and most probably both cohorts were comparable at time of transplantation. Second, this population has already acquired a significant increase in cardiovascular risk by virtue of the development of ESRD. 24 It may be that the relative contribution of BMI to long-term cardiovascular risk becomes undetectable in the presence of this. Third, it is likely that obese kidney transplant recipients undergo more frequent medical review than obese individuals in the general population, which may be associated with improved management of other cardiovascular risk factors related to obesity. There is limited published data which addresses the relationship between BMI at the time of renal transplantation and the subsequent risk of developing cancer. Our study found that obese patients had a lower incidence of malignancy. One possible theory is that obesity may alter the metabolism and bioavailability of immunosuppressive medication, 7 leading to a reduced effective total immunosuppressive burden and an associated lower incidence of malignancy compared to nonobese recipients. It is also possible that the small magnitude of the increased risk of cancer observed in obese patients in the general population becomes insignificant in the context of other risk factors, such as previous dialysis treatment and long-term immunosuppression present in a renal transplant cohort. In addition, it is likely that some of the observed association between obesity and cancer in the general population is related to the development of diabetes mellitus and retrospective studies suggest that treatment with metformin, thiazolidinediones and insulin may reduce overall cancer risk. 21 Due to their frequency of follow up, obese renal transplant recipients are more likely to have diabetes mellitus identified at an early stage and commence treatment with these agents before hyperglycaemia manifests an effect on tumour cell growth. 21 In the general population, obesity and type 2 diabetes mellitus are strongly associated. Consistent with both this and the literature in renal transplant recipients, 19 we demonstrated an association between BMI at the time of transplant and the development of post-transplant diabetes mellitus in our cohort.
In the general population, obesity is associated with an increased risk of chronic kidney disease which remains after adjustment for related comorbidities. 15 Obesity results in glomerular hyperfiltration, proteinuria and glomerulomegaly with secondary glomerulosclerosis and interstitial fibrosis. 14, 15 Adipose tissue has both immune and endocrine functions which may also contribute to obesity-related kidney disease. 14, 16 Graft damage by similar mechanisms after kidney transplantation could be anticipated. In addition, obesity may alter metabolism and bioavailability of immunosuppressive medication, potentially increasing the risk of chronic immunological injury. 12 There is no consensus of opinion in the literature about the impact of BMI on long-term graft survival. Our study found no association between BMI and graft survival at a minimum of 10 years post-transplant. Of note, smoking status was the single modifiable factor in our study which influenced graft survival. In this cohort, BMI had no significant impact on recipient survival. This may relate to the inherent limitation of BMI, although it is commonly used as a measure of obesity it is well recognized that it is an imperfect measure of adiposity. It cannot differentiate visceral adiposity from muscle mass and nonvisceral fat mass. A study of 990 renal transplant recipients in Budapest found no clear association between BMI and mortality. However, in this cohort a high waist circumference was associated with a higher mortality and this association was more pronounced after adjustment for BMI. 16 It would be interesting to note other parameters which take into account the fat distribution of the recipient, e.g. waist circumference or hipwaist ratio. However, it is possible that the demonstrated lack of impact of obesity on recipient transplant survival is an extension of the 'obesity-paradox' well recognized in maintenance dialysis patients. 25, 26 In this population increasing BMI is associated with longer survival. It is postulated that this 'reverse epidemiology' does not reflect a protective effect of adiposity but rather the absence of a chronic inflammatory state, protein-energy malnutrition, with or without an associated underlying illness. Thus, those with a higher BMI at time of transplant may be healthier and be conferred a survival advantage, at least in the short-term. The ubiquitous weight gain noted in transplant recipients may be consistent with chronic malnourishment at the time of transplantation. The lack of association between obesity and recipient survival in our population is consistent the report of a meta-analysis which included 17 studies and 138 000 patients. 9 This study explored the impact of BMI at the time of transplant on graft and recipient outcomes and found no significant association between a greater BMI and increased risk of cardiovascular complications, This contrasts with the results of a recently published European study which found an association between higher BMI in stable kidney transplant recipients and cardiovascular events over a 5-year follow-up period. 10 One potential explanation for this is that our study recruited consecutive incident kidney transplant recipients while the other study investigated the impact of BMI in prevalent, stable kidney transplant recipients with good kidney function (eGFR 53.4 6 19.7 ml/ min/1.73 m 2 ). It is possible that conventional risk factors have a greater relative impact on risk of cardiovascular events in recipients who are many years post-transplant with good kidney function when the additional risk conferred by ESRD and dialysis will have waned. In keeping with this, the European cohort had more of the other conventional risk factors for cardiovascular disease, including older age and previous history of cardiovascular events, compared to our cohort. It is not possible to address post-transplant obesity at the time of transplantation given the impossibility of identifying which recipients will be affected. However, this study does suggest that it is important to address obesity in the stable post-transplant population because of an increased cardiovascular risk. 10 The strengths of this study are the availability of prospectively collected, comprehensive follow-up data in an unselected kidney transplant recipient cohort for three decades. This is the longest period of follow up identified in the literature. The detailed nature of this information facilitates in depth analysis of the impact of BMI at the time of transplantation, which is not possible with large scale registry data. The main weakness of this study is the very small numbers of morbidly obese patients. It is difficult to obtain data on such patients, as very few were transplanted historically.
This study has found that obese renal transplant recipients have an increased risk of post-transplant diabetes mellitus; however, this neither translates into an increased risk of cardiovascular disease or malignancy nor does it impact long-term graft or recipient survival. Potential recipients should not be excluded from transplantation solely on the basis of BMI but should have their individual risk of transplantation stratified, based on comorbidity and considering the risk of death on maintenance dialysis. It is clear that obese patients can receive a similar overall survival benefit from transplantation as non-obese individuals. 
